

02-06-02

/-

Please type a plus sign (+) inside this box -+ +

PTO/SB/05 (11-00)
Approved for use through 10/31/2002. QMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. 3414/1

First Inventor Joel Krasnow

Title Methods of Using a Cyclooxygenase-2 Inhibitor and Sex Steroids...

Express Mail Label No. EV001321491US (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, D.C. 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or Computer (Submit an original, and a duplicate for fee processing) Program (Appendix) Applicant claims small entity status. ... 8. Nucleotide and/or Amino Acid Sequence Submission 2 See 37 CFR 1.27. (if applicable, all necessary) Computer Readable Form (CRF) a. [Total Pages Specification 101 17 (preferred arrangement set forth below) Specification Sequence Listing on: - Descriptive title of the invention CD-ROM or CD-R (2 copies); or - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D paper - Reference to sequence listing, a table, or a computer program listing appendix Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention **ACCOMPANYING APPLICATION PARTS** - Brief Description of the Drawings (if filed) Assignment Papers (cover sheet & document(s)) - Detailed Description 9. - Claim(s) 37 CFR 3.73(b) Statement Power of Attorney 10. Abstract of the Disclosure (when there is an assignee) English Translation Document (if applicable) 11. 4. Drawing(s) (35 U.S.C. 113) [Total Sheets Information Disclosure Copies of IDS 12. Statement (IDS)/PTO-1449 Citations [Total Pages Oath or Declaration 13. Preliminary Amendment Newly executed (original or copy) a. Return Receipt Postcard (MPEP 503) 14. (Should be specifically itemized) Copy from a prior application (37 CFR 1.63(d)) Certified Copy of Priority Document(s) b. (for continuation/divisional with Box 18 completed) 15. (if foreign priority is claimed) **DELETION OF INVENTOR(S)** Request and Certification under 35 U.S.C. 122 i. 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 Signed statement attached deleting inventor(s) òr its èquivalent. named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). unexecuted Declaration 17. 🗸 Other: Application Data Sheet. See 37 CFR 1.76 If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, 18 or in an Application Data Sheet under 37 CFR 1.76: Continuation-in-part (CIP) of prior application No.: Divisional Continuation Prior application information: Group / Art Unit For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. CORRESPONDENCE ADDRESS Correspondence address below Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) Pharmacia Corporation Name Corporate Patent Department 800 North Lindbergh Blvd. Address Mail Zone O4E Zip Code State Missouri 63167 City St. Louis Fax 314-694-7256 Country **United States** Telephone 314-694-4474 Name (Print/Type) Philip B. Polster, II Registration No. (Attorney/Agent) 43,864

Burden Hour Statement: This form sestimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

8	1	,3	7	Λ		n	Λ
J	1	••	1	v	٠	v	v

Complete if Known				
Application Number	TBA			
Filing Date	ТВА			
First Named Inventor	Joel Krasnow			
Examiner Name	ТВА			
Group Art Unit	ТВА			
Attorney Docket No.	3414/1			

METHOD OF PAYMENT		FEE CALCULATION (continued)						
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:		3. ADDITIONAL FEES arge Entity Small Entity						
Deposit Account 19-1025	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid		
Number 17-1023	105	130	205		Surcharge - late filing fee or oath			
Deposit Account Name Pharmacia Corporation	127	50	227	25	Surcharge - late provisional filing fee or cover sheet			
Charge Any Additional Fee Required		130	139	130	Non - English specification			
Under 37 CFR §§ 1.16 and 1.17	147	2,520	147	2,520	For filing a request for ex parte reexamination			
Applicant claims small entity status. See 37 CFR § 1.27	112	920*	112	920*	Requesting publication of SIR prior to Examiner action			
2. Payment Enclosed:		1,840*	113	1,840*	Requesting publication of SIR after Examiner action			
Check Credit card Money Other		110	215	55	Extension for reply within first month			
FEE CALCULATION	116	390	216	195	Extension for reply within second month			
1. BASIC FILING FEE	117	890	217	445	Extension for reply within third month			
Large Entity Small Entity	118	1,390	218	695	Extension for reply within fourth month			
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	128	1,890	228	945	Extension for reply within fifth month			
101 710 201 355 Utility filing fee 740.00	119	310	219	155	Notice of Appeal			
106 320 206 160 Design filing fee	120	310	220	155	Filing a brief in support of an appeal			
107 490 207 245 Plant filing fee	121	270	221	135	Request for oral hearing			
108 710 208 355 Reissue filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding			
114 150 214 75 Provisional filing fee	140	110	240	55	Petition to revive - unavoidable			
SUBTOTAL (1) \$740.00	141	1,240	241	620	Petition to revive - unintentional			
O EVERA OLAMA EEEO		1,240	242	620	Utility issue fee (or reissue)			
2. EXTRA CLAIM FEES Fee from	143	440	243	220	Design issue fee			
Extra Claims below Fee Paid Total Claims 55 -20** = 35 X 18.00 = 630.00 Independent 2 -3** = 0 X 0.00 = 0.00		600	244	300	Plant issue fee			
		130	122	130	Petitions to the Commissioner			
Claims U = 0.00 = 0.00 Multiple Dependent	123	50	123	50	Processing fee under 37 CFR § 1.17(q)			
Large Entity Small Entity	126	180	126	180	Submission of Information Disclosure Statement			
Fee Fee Fee Fee Description Code (\$) Code (\$)	581	40	581	40	Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20	146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))			
102 80 202 40 Independent claims in excess of 3 104 270 204 135 Multiple dependent claim, if not paid	149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))			
109 80 209 40 ** Reissue independent claims	179	710	279	355	Request for Continued Examination (RCE)			
over original patent	169	900	169	900	Request for expedited examination			
110 18 210 9 *** Reissue claims in excess of 20 and over original patent		of a design application						
		Other fee (specify)						
SUBTOTAL (2) \$630.00								
**or number previously paid, if greater, For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3)							
CURMITTED BY					Complete (if applicable)	=		

Registration No. (Attorney/Agent) Name (Print/Type Philip B. Polster 43,864 Telephone 314-694-9094 Signature February 4, 2002

> WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

CERTIFICATE OF Applicant(s): Joel Kras	MAIL" (37 CFR 1.16,	Docket No. 3414/1		
Serial No. TBA	Filing Date TBA	Examiner TBA	Group Art Unit TBA	
Invention: METHOD (THERAPY	DF USING A CYCLOOXYGENA FOR THE TREATMENT AND P	SE-2 INHIBITOR AND SEX STERO PREVENTION OF DYSMENORRHI	OIDS AS A CMBINATION EA	
is being deposited with 37 CFR 1.10 in an element (Date (Dat	(Identify type of the United States Postal Servinvelope addressed to: The Assistant 4, 2002	pecification; unexecuted Declaration of correspondence) ice "Express Mail Post Office to Add stant Commissioner for Patents, W Philip B. Polster,	ashington, D.C. 20231	
		(Typed or Printed Name of Person Mailing (Signarire of Person Mailing Corre EV001321491US ("Express Mail" Mailing Label I	(Correspondence) IT spondence)	

Note: Each paper must have its own certificate of mailing.